Search
Neuphoria Therapeutics Inc
NEUPAdd to Watchlist
3.550USD
-0.820-18.76%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
19.09MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of Neuphoria Therapeutics Inc is 6.00, ranking 329 out of 387 in the Biotechnology & Medical Research industry. The average price target is 20.00, with a high of 21.00 and a low of 2.30.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
7.000
Target Price
+60.18%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Neuphoria Therapeutics Inc
NEUP
1
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Neuphoria Therapeutics Inc's price target?
Analysts forecast that Neuphoria Therapeutics Inc's price target is USD 20.00, with the highest forecast at USD 21.00 and the lowest forecast at USD 2.30.
How have Neuphoria Therapeutics IncNEUP's recent earnings per share performed?
The market expectation was USD -0.09, while Neuphoria Therapeutics IncNEUP's earnings per share (EPS) for the previous quarter was USD 0.41. EPS for the next quarter is expected at USD -0.56.
What is the analyst rating for Neuphoria Therapeutics Inc?
Based on the ratings of Neuphoria Therapeutics Inc's stock from 1 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.